Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 35Other solid neoplasm 35Gynecologic 3Gastrointestinal 3Lymphoid 2Genitourinary 2Breast 2Sarcoma 1Myeloid 1Head & Neck 1Dermatologic 1

Conditions

Uveal Melanoma 1Stomach Neoplasms 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lung Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

ruxolitinib 1avelumab 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Imatinib Mesylate 1Drug Therapy 1Cisplatin 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Cisplatin × Myeloid × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡